Background: Ranked 5th in domestic market with Net Sales of INR 94.6bn with 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CAGR - 27%, PAT CAGR - 25%. Vertically integrated with strengths in manufacturing and IP based products.12 Mfg sites of which 2 in Japan. API sites -5, Formulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales with US-38%, ROW-17%, Japan-12%, Europe-3%. Formulations- 90% of sales and API -10%. In US Generics account for 78%, branded formulations-22%. Plans 120 launches in 3-4 yrs - addressable market...